Studies cabozantinib and nivolumab in older adults with kidney cancer
Looks at real-life use of two cancer drugs in older people with advanced kidney cancer.
Plain-language title generated from the registry record
Registry title: Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Key facts
- Where
- Angers, Dijon, Lyon, Paris, Toulouse, Tours, and Villejuif, FranceSee the 7 sites
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 70 or older with advanced or spread kidney cancer who have not yet had treatment for the spread disease.
- Age
- 70 years or older
- Sex
- All sexes can join.
- Disease stage
- Confirmed advanced or metastatic renal-cell carcinoma (kidney cancer). Performance Status 0 to 2.
- Earlier treatment
- Must not have had earlier treatment for the metastatic (spread) disease.
Main reasons for not taking part
- Performance Status above 2
- Symptomatic untreated brain metastasis or active auto-immune disease needing systemic immunosuppressant treatment
- Any severe heart, blood-vessel or blood-clot event in the last three months
- Any situation where only palliative care is advised
- Taking part in another clinical study with an investigational product in the last four weeks
Read by machine on 12 November 2026.
Where in France
- Institut de Cancérologie de l'Ouest - AngersAngers, FranceContact: Elouen BOUGHALEM, MDNot yet recruiting
- Centre Georges François LeclercDijon, FranceContact: Leila BENGRINE, MDNot yet recruiting
- Centre Leon BerardLyon, FranceContact: Helen BOYLE, MDNot yet recruiting
- Hôpital TenonParis, FranceContact: Djamel GHEBRIOU, MDNot yet recruiting
- Institut Universitaire Du Cancer Toulouse- Oncopole Claudius RegaudToulouse, FranceContact: Loïc MOUREY, MDNot yet recruiting
- CHU Tours Hôpital BretonneauTours, FranceContact: Mathilde CANCEL, MDNot yet recruiting
- Gustave RoussyVillejuif, FranceContact: Maxime FRELAUT, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Gustave Roussy, Cancer Campus, Grand Paris
- Trial code
- NCT06934057
- Record updated
- 24 September 2025
- Original description
The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancerRead full original descriptionShow less
Cabozantinib and Nivolumab Among Older Patients With Renal-cell Carcinoma, a Prospective Cohort With Geriatric, Pharmacologic and Patient-reported-outcome Evaluation
The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer
Inclusion: Patients ≥ 70 years-old; Confirmed advanced or metastatic renal-cell carcinoma; Patients not previously treated in metastatic setting; Performance Status 0 to 2; Sexually active male patients must agree to use condom during the study and for at least 5 months after the last study treatment administration. Also, it is recommended their women of childbearing potential partner use a highly effective method of contraception; Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol; Patients must be affiliated to a social security system or beneficiary of the same.
Exclusion: Participation in another clinical study with an investigational product during the last four weeks and while on study treatment (Patients may be included in CABOLD if they are included in the arm B of CARE1 study EUCT N° 2023-503317-29-00); Any condition that represent a contraindication to Cabozantinib and/or Nivolumab, as described in summaries of products characteristics, including symptomatic untreated brain metastasis or active auto-immune disease requiring systemic immunosuppressant/modulator (thyroid or adrenal disorder are not an exclusion criteria); Performance Status > 2; Any severe cardiovascular or thrombo-embolic event in the last three months; Any situation for which exclusive palliative care intervention is recommended; Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.